Reducing the Duration of Untreated Psychosis (ReduceDUP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03102151|
Recruitment Status : Recruiting
First Posted : April 5, 2017
Last Update Posted : April 5, 2017
|Condition or disease||Intervention/treatment|
|First Episode Psychosis||Other: Community Campaign La CLAVE|
|Study Type :||Observational|
|Estimated Enrollment :||145 participants|
|Observational Model:||Ecologic or Community|
|Official Title:||Reducing the Duration of Untreated Psychosis Through Community Education|
|Study Start Date :||May 2014|
|Estimated Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||September 2018|
- Other: Community Campaign La CLAVE
A community campaign to teach community residents and professional networks the signs and symptoms of psychosis using social media, community talks, and advertising.
- Latency to Treatment (LTT) a novel interview based assessment tool to measure the Duration of Untreated Psychosis [ Time Frame: At the time of recruitment into the study ]The time from the onset of psychosis to the time the subject receives appropriate mental health treatment. The metric is number of weeks that the person went without treatment from illness onset. The number of weeks is the variable of interest that will be aggregated.
- Psychosis literacy, a questionnaire based inquiry for which the respondents answer either open-ended questions (e.g., What is serious mental Illness?) or "Yes-no" questions ("e.g., Can you recognize a serious mental illness in others?) [ Time Frame: At the time of recruitment in to study ]The responses to the interview are either written down or audio-recorded. Raters then listen or read the responses and code them. The responses are aggregated as frequencies (e.g., the number of symptoms identified) or as percentages (e.g., the proportion of respondents who reported that they can recognize a serious mental illness in others).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03102151
|United States, California|
|San Fernando Mental Health Center||Recruiting|
|Granada Hills, California, United States, 91344|
|Contact: Alex Kopelowicz, MD firstname.lastname@example.org|
|Principal Investigator:||Steven Lopez, PhD||University of Southern California|